These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 29133589)

  • 21. Precision medicine in pediatric oncology.
    Forrest SJ; Geoerger B; Janeway KA
    Curr Opin Pediatr; 2018 Feb; 30(1):17-24. PubMed ID: 29189430
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Universal Genomic Testing: The next step in oncological decision-making or a dead end street?
    Holch JW; Metzeler KH; Jung A; Riedmann K; Jost PJ; Weichert W; Kirchner T; Heinemann V; Westphalen CB
    Eur J Cancer; 2017 Sep; 82():72-79. PubMed ID: 28648701
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Somatic Mutation Analysis of Human Cancers: Challenges in Clinical Practice.
    Tsongalis GJ; Coleman WB
    J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S60-S66. PubMed ID: 28921651
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genomic data integration by WON-PARAFAC identifies interpretable factors for predicting drug-sensitivity in vivo.
    Kim Y; Bismeijer T; Zwart W; Wessels LFA; Vis DJ
    Nat Commun; 2019 Nov; 10(1):5034. PubMed ID: 31695042
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improved anticancer drug response prediction in cell lines using matrix factorization with similarity regularization.
    Wang L; Li X; Zhang L; Gao Q
    BMC Cancer; 2017 Aug; 17(1):513. PubMed ID: 28768489
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Breast cancer: The translation of big genomic data to cancer precision medicine.
    Low SK; Zembutsu H; Nakamura Y
    Cancer Sci; 2018 Mar; 109(3):497-506. PubMed ID: 29215763
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug-biomarker co-development in oncology - 20 years and counting.
    Twomey JD; Brahme NN; Zhang B
    Drug Resist Updat; 2017 Jan; 30():48-62. PubMed ID: 28363335
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multi-Omics Model Applied to Cancer Genetics.
    Pettini F; Visibelli A; Cicaloni V; Iovinelli D; Spiga O
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072237
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Personalization of Therapy: Molecular Profiling Technologies and Their Application.
    Zeron-Medina J; Ochoa de Olza M; Braña I; Rodon J
    Semin Oncol; 2015 Dec; 42(6):775-87. PubMed ID: 26615125
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Making Sense of Genetic Information: The Promising Evolution of Clinical Stratification and Precision Oncology Using Machine Learning.
    Baptiste M; Moinuddeen SS; Soliz CL; Ehsan H; Kaneko G
    Genes (Basel); 2021 May; 12(5):. PubMed ID: 34065872
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Omics Profiling in Precision Oncology.
    Yu KH; Snyder M
    Mol Cell Proteomics; 2016 Aug; 15(8):2525-36. PubMed ID: 27099341
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Deep Learning Framework for Predicting Response to Therapy in Cancer.
    Sakellaropoulos T; Vougas K; Narang S; Koinis F; Kotsinas A; Polyzos A; Moss TJ; Piha-Paul S; Zhou H; Kardala E; Damianidou E; Alexopoulos LG; Aifantis I; Townsend PA; Panayiotidis MI; Sfikakis P; Bartek J; Fitzgerald RC; Thanos D; Mills Shaw KR; Petty R; Tsirigos A; Gorgoulis VG
    Cell Rep; 2019 Dec; 29(11):3367-3373.e4. PubMed ID: 31825821
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cancer Bioinformatics for Updating Anticancer Drug Developments and Personalized Therapeutics.
    Lu DY; Qu RX; Lu TR; Wu HY
    Rev Recent Clin Trials; 2017; 12(2):101-110. PubMed ID: 28190390
    [TBL] [Abstract][Full Text] [Related]  

  • 34. National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network.
    Abrams J; Conley B; Mooney M; Zwiebel J; Chen A; Welch JJ; Takebe N; Malik S; McShane L; Korn E; Williams M; Staudt L; Doroshow J
    Am Soc Clin Oncol Educ Book; 2014; ():71-6. PubMed ID: 24857062
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Precision oncology based on omics data: The NCT Heidelberg experience.
    Horak P; Klink B; Heining C; Gröschel S; Hutter B; Fröhlich M; Uhrig S; Hübschmann D; Schlesner M; Eils R; Richter D; Pfütze K; Geörg C; Meißburger B; Wolf S; Schulz A; Penzel R; Herpel E; Kirchner M; Lier A; Endris V; Singer S; Schirmacher P; Weichert W; Stenzinger A; Schlenk RF; Schröck E; Brors B; von Kalle C; Glimm H; Fröhling S
    Int J Cancer; 2017 Sep; 141(5):877-886. PubMed ID: 28597939
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Machine learning for precision medicine.
    MacEachern SJ; Forkert ND
    Genome; 2021 Apr; 64(4):416-425. PubMed ID: 33091314
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Next generation sequencing in cancer: opportunities and challenges for precision cancer medicine.
    Paolillo C; Londin E; Fortina P
    Scand J Clin Lab Invest Suppl; 2016; 245():S84-91. PubMed ID: 27542004
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In silico drug combination discovery for personalized cancer therapy.
    Jeon M; Kim S; Park S; Lee H; Kang J
    BMC Syst Biol; 2018 Mar; 12(Suppl 2):16. PubMed ID: 29560824
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A gentle introduction to understanding preclinical data for cancer pharmaco-omic modeling.
    Piyawajanusorn C; Nguyen LC; Ghislat G; Ballester PJ
    Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 34368843
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacogenomic biomarkers for personalized cancer treatment.
    Rodríguez-Antona C; Taron M
    J Intern Med; 2015 Feb; 277(2):201-217. PubMed ID: 25338550
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.